[Retracted] Knockdown of lncRNA HOXD-AS2 Improves the Prognosis of Glioma Patients by Inhibiting the Proliferation and Migration of Glioma Cells

Table 3

Correlations between the expression of HOXD-AS2 and clinicopathologic parameters.

Parameter	Patients (n)	Expression of HOXD-AS2 (n)			value
		Low (n, %)	Middle (n, %)	High (n, %)
Total	87	29 (33.3%)	29 (33.3%)	29 (33.3%)
Age
<55	52	22 (42.3%)	13 (25.0%)	17 (32.7%)	0.054
≥55	35	7 (20.0%)	16 (45.7%)	12 (34.3%)
Gender
Male	48	15 (31.3%)	16 (33.3%)	17 (35.4%)	0.870
Female	39	14 (35.9%)	13 (33.3%)	12 (30.8%)
Tumor size
<5 cm	30	14 (46.7%)	9 (30.0%)	7 (23.3%)	0.137
≥5 cm	57	15 (26.3%)	20 (35.1%)	22 (38.6%)
Resection
Total	52	22 (42.3%)	17 (32.7%)	13 (25.0%)	0.140
Subtotal	29	5 (17.2%)	11 (37.9%)	13 (44.8%)
Partial	6	2 (33.3%)	1 (16.7%)	3 (50.0%)
Pathology
Low grade	40	20 (50.0%)	7 (17.5%)	13 (32.5%)	0.003
High grade	47	9 (19.1%)	22 (46.8%)	16 (34.0%)